Adherence in allergen immunotherapy: Current situation and future implications

Francesca Gehrt; Qingqing Xu; Ilaria Baiardini; Giorgio Walter Canonica; Oliver Pfaar

doi:10.5414/ALX02318E

Adherence in allergen immunotherapy: Current situation and future implications

Allergol Select. 2022 Nov 21:6:276-284. doi: 10.5414/ALX02318E. eCollection 2022.

Authors

Francesca Gehrt¹, Qingqing Xu^{2

3}, Ilaria Baiardini^{4

5}, Giorgio Walter Canonica^{4

5}, Oliver Pfaar¹

Affiliations

¹ Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-University Marburg, Marburg, Germany.
² Department of Allergy, Beijing Tong Ren Hospital, Capital Medical University.
³ Department of Otolaryngology Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, PR China.
⁴ Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano, and.
⁵ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Abstract

Allergen immunotherapy (AIT) is the only disease-modifying treatment in allergy. However clinical trials as well as real-life studies revealed poor treatment adherence. This article is intended to provide an overview of the current literature of the last 10 years, to outline reasons for poor treatment adherence in AIT and to provide possible solutions for improving adherence.

Keywords: adherence; allergen immunotherapy; persistence; subcutaneous; sublingual.

Publication types

Review